` Mural Oncology: Immuno Oncology Quiz
Test Your
IO IQ
How Is Your
Immuno-Oncology
Knowledge?
Are you ready to be challenged?
Answer questions and you will see
how you did on this quiz
Question 1
Cytokines are proteins integral to the functioning
of the immune system.
Question 2
Interleukins (ILs) are:
Question 3

Interleukin-2 (IL-2) stimulates the
expansion of cytotoxic CD8+ T cells via
the intermediate-affinity 2-chain (β,γ) receptor.

Question 4

Interleukin-2 (IL-2) is a cytokine whose action
is mediated via:

Question 5

Interleukin-2 (IL-2) receptors (either intermediate-affinity
or high-affinity) are found on various types of
immune cells including:

Question 6

Which of the following about the tumor effects of interleukin-2 (IL-2) is correct:

Question 7

Which of the following cells are associated with cytotoxic
anti-tumor effects?

Question 8

Drag the immune cell labels onto the correct
blue tile based on their role in cancer.

NK Cell
Treg Cell
CD8+ T Cell
Anti-tumor effects
Drag immune cell label(s) here
Not sure
Drag immune cell label(s) here
Tumor evasion effects
Drag immune cell label(s) here
NK Cell
Treg Cell
CD8+ T Cell
Question 9

Drag and drop the cells onto the correct images based on the
type of interleukin-2 (IL-2) receptor they predominantly express.

NK Cell
Treg Cell
CD8+ T Cell
Drag immune cell label(s) here
Drag immune cell label(s) here
NK Cell
Treg Cell
CD8+ T Cell
Question 10

Match the correct statements:
Select a blue tile and a matching green tile to correctly complete the statement

Binding of IL-2 to the intermediate-affinity 2-chain IL-2 receptor
Binding of IL-2 to the high-affinity 3-chain
IL-2 receptor
would be expected to stimulate the anti-tumor effects of IL-2
would be expected to inhibit the anti-tumor effects of IL-2
Binding of IL-2 to the intermediate-affinity 2-chain IL-2 receptor
Binding of IL-2 to the high-affinity 3-chain
IL-2 receptor
Question 11

Identify where IL-2 and PD-1/PD-L1 pathways
play a role in the cancer immunity cycle.

Select 2 stages to answer

Release of cancer cell antigens
1
Cancer antigen
presentation
2
Priming
and activation
3
Trafficking of
T cells to tumors
4
Infiltration of T cells
into tumors
5
Recognition of
cancer cells by T cells
6
Killing of cancer cells
7
Question 12

Which of the following cell types are
associated with immunosuppressive effects?

Question 13

Antigen-presenting cells (APCs) are a heterogeneous group
of immune cells that mediate the cellular immune response by:

Question 14

What are the three main types of antigen-presenting cells?

Question 15

Match the cytotoxic effector cell with the type of
immunity with which it is most commonly associated:

NK Cell
CD8+ T Cell
Innate immunity
Adaptive immunity
Innate immunity
Adaptive immunity
Question 16

Upon secretion, interleukin-12 and -18 (IL-12, IL-18) can potentially
stimulate NK and T cells to drive production of which interferon?

Question 17

Interferon-γ can have a variety of anti-tumor benefits
that include which of the following?

Question 18

Match the cell type and cytokine with the type of
cancer-immunity processes with which it is primarily associated:

Anti-tumor immunity
Drag cell type and cytokine here
Both anti-tumor immunity
AND tumor-induced
immunosuppression
Drag cell type and cytokine here
Tumor-induced
immunosuppression
Drag cell type and cytokine here
IL-6
IL-18
TNF-α
TGF-β
CD8+ T cells
NK cells
HD-IL-2
IL-12
Mature-DC
Treg cells
MDSCs
VEGF
IL-10
IL-6
IL-18
TNF-α
TGF-β
CD8+ T cells
NK cells
HD-IL-2
IL-12
Mature-DC
Treg cells
MDSCs
VEGF
IL-10
Question 19
Cytokines are proteins made in response to pathogens
and other antigens that regulate and mediate
inflammatory and immune responses.
Question 20
Interleukin-2 (IL-2) is a cytokine that stimulates the activation
and expansion of anti-tumor CD8+ T cells.
Question 21

Binding of IL-2 to the intermediate-affinity 2-chain
IL-2 receptor would be expected to:

Question 22

The effects of the PD-1/PD-L1 pathway on the immune system are:

The quiz is complete.

Thank you for participating. Your final score was

0/0

Finish